# Legend Biotech Corp: overview

LEGN · Nasdaq · CIK 1801198 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/legn.md) · [Financials](/companies/legn/financials.md) · [Filings](/companies/legn/filings.md) · [Insiders](/companies/legn/insiders.md)

Revenue is not reported in this company’s XBRL financial statements.

## Last eight quarters

Not reported.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [68.8](/filings/0001801198-24-000021.md) | [117](/filings/0001801198-25-000012.md) | [285](/filings/0001801198-25-000012.md) | [627](/filings/0001801198-25-000012.md) | [1,029](/filings/0001801198-26-000008.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | [(185.2%)](/filings/0001801198-26-000008.md) | [(49.3%)](/filings/0001801198-26-000008.md) | [(13.3%)](/filings/0001801198-26-000008.md) |
| Net margin | % | [(586.4%)](/filings/0001801198-24-000021.md) | [(381.5%)](/filings/0001801198-25-000012.md) | [(181.8%)](/filings/0001801198-25-000012.md) | [(28.2%)](/filings/0001801198-25-000012.md) | [(28.8%)](/filings/0001801198-26-000008.md) |
| Diluted EPS | $ per share | [(1.43)](/filings/0001801198-24-000021.md) | [(1.40)](/filings/0001801198-25-000012.md) | [(1.47)](/filings/0001801198-26-000008.md) | [(0.48)](/filings/0001801198-26-000008.md) | [(0.81)](/filings/0001801198-26-000008.md) |
| Free cash flow | $m | [(241)](/filings/0001801198-24-000021.md) | [(222)](/filings/0001801198-25-000012.md) | [(413)](/filings/0001801198-26-000008.md) | [(158)](/filings/0001801198-26-000008.md) | [(129)](/filings/0001801198-26-000008.md) |

- Revenue. XBRL Revenue: ifrs-full:Revenue; Revenue: ifrs-full:RevenueFromContractsWithCustomers.
- Gross margin (gross profit / revenue). XBRL Revenue: ifrs-full:Revenue; Revenue: ifrs-full:RevenueFromContractsWithCustomers.
- Operating margin (operating income / revenue). XBRL Revenue: ifrs-full:Revenue; Operating income: ifrs-full:ProfitLossFromOperatingActivities; Revenue: ifrs-full:RevenueFromContractsWithCustomers.
- Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLossAttributableToOwnersOfParent; Revenue: ifrs-full:Revenue; Net income: ifrs-full:ProfitLoss; Revenue: ifrs-full:RevenueFromContractsWithCustomers.
- Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/legn/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $840.2m | 29,093,899 |  | Added +3,397,159 |
| [DEERFIELD MANAGEMENT COMPANY, L.P.](/funds/1009258.md) | 2026-06-30 | $235.0m | 8,137,638 |  | Added +450,000 |
| [MONTANOVA CAPITAL, LLC](/funds/1569064.md) | 2026-06-30 | $204.2m | 7,070,000 |  | Reduced −511,029 |
| [HHLR ADVISORS, LTD.](/funds/1762304.md) | 2026-06-30 | $172.8m | 5,984,550 |  | Unchanged |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $136.5m | 4,726,534 |  | Added +41,991 |
| [WESTFIELD CAPITAL MANAGEMENT CO LP](/funds/1177719.md) | 2026-06-30 | $127.9m | 4,430,063 |  | Reduced −1,333,412 |
| [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $105.8m | 3,662,315 |  | Added +2,198,203 |
| [Point72 Asset Management, L.P.](/funds/1603466.md) | 2026-06-30 | $88.8m | 3,076,124 |  | Reduced −809,893 |
| [Kynam Capital Management, LP](/funds/1907884.md) | 2026-06-30 | $86.7m | 3,001,205 |  | Added +1,424,910 |
| [Assenagon Asset Management S.A.](/funds/1546007.md) | 2026-06-30 | $55.3m | 1,915,056 |  | New +1,915,056 |

## Recent filings

[All 384 filings](/companies/legn/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-15 | 12:00 ET | [6-K](/filings/0001171843-26-006646.md) | Report of a foreign private issuer, period 2026-10-15 | 0001171843-26-006646 |
| 2026-10-13 | 11:30 ET | [6-K](/filings/0001171843-26-006593.md) | Report of a foreign private issuer, period 2026-10-13 | 0001171843-26-006593 |
| 2026-09-25 | 11:00 ET | [6-K](/filings/0001171843-26-006229.md) | Report of a foreign private issuer, period 2026-09-24 | 0001171843-26-006229 |
| 2026-09-24 | 20:00 ET | [6-K](/filings/0001171843-26-006215.md) | Report of a foreign private issuer, period 2026-09-24 | 0001171843-26-006215 |
| 2026-09-15 | 12:00 ET | [6-K](/filings/0001171843-26-006050.md) | Report of a foreign private issuer, period 2026-09-15 | 0001171843-26-006050 |
| 2026-09-14 | 12:00 ET | [6-K](/filings/0001171843-26-006027.md) | Report of a foreign private issuer, period 2026-09-14 | 0001171843-26-006027 |
| 2026-08-18 | 20:01 ET | [6-K](/filings/0001171843-26-005623.md) | Report of a foreign private issuer, period 2026-08-18 | 0001171843-26-005623 |
| 2026-08-11 | 11:53 ET | [6-K](/filings/0001801198-26-000022.md) | Report of a foreign private issuer, period 2026-06-30 | 0001801198-26-000022 |
| 2026-08-06 | 20:05 ET | [6-K](/filings/0001171843-26-005318.md) | Report of a foreign private issuer, period 2026-08-06 | 0001171843-26-005318 |
| 2026-07-27 | 10:02 ET | [6-K](/filings/0001193125-26-316760.md) | Report of a foreign private issuer, period 2026-07-27 | 0001193125-26-316760 |

## Latest annual report

[Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001801198-26-000008.md), filed Mar 10, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1801198
- Tickers: LEGN
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: E9
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.